Skip to content
Alert Sign Hackensack Meridian Health has appointments available for Pfizer and Moderna COVID-19 vaccines. Sign up today to get your appointment within 24 hours. Close Alert Box
Hackensack UMC logo
  • GIVE NOW
  • 1-844-HMH-WELL
  • Find a Doctor
  • About
  • Location
  • Team
  • Services
  • Research
  • Donate

Clinical Trials

Find a DoctorOur LocationsAwards and Accreditation

Home  › Research  ›  Trials

Search for:

A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma.


A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis


Phase II Study of Nivolumab/Ipilimumab plus Cabozantinib in Patients with Unresectable Advanced Melanoma


A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCCC) (KEYNOTE-630)


A Phase IB Trial Of Neoadjuvant AMG 232 Concurrent With Preoperative Radiotherapy In Wild-Type P53 Soft Tissue Sarcoma (STS)


A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma.


A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma


A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.


A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)


A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma


Posts navigation

Next
View all types of trials

Types of Cancer / Trials

  • All
  • Breast
  • Breast-Surgical Oncology
  • Gastrointestinal
  • Genito-Urinary
  • Gynecologic
  • Head and Neck
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Neuro-oncology
  • Phase 1
  • Phase 1 (GI)
  • Phase 1 (L)
  • Phase 1 (Thoracic)
  • Skin and Soft Tissue
  • Thoracic (Lung)
  • Transplant

Recently Added Trials

  • A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy
  • A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma.
  • A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma
  • A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
  • A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of NivolumabVersus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human EpidermalGrowth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

© 2021 Hackensack Meridian Health

  • About Us
  • Careers
  • Classes & Events
  • Contact Us
  • Donate
  • Financial Practices
  • Patients & Visitors
  • Privacy
  • Terms & Conditions